NeoGenomics NEO Medicare and other government — NET REVENUE

Other product segments

Similar metrics at other companies

ARD

ARDTMedicare — Net patient service revenue

$669.17M+12.3%

EHCMedicare — Net operating revenues

$1.04B+6.5%

THCMedicare — Net operating revenues

$565M+3.1%

SEMMedicare — Revenue

$436.55M+11.8%

RDNTMedicare — Total consolidated revenues

$137.18M+26.8%

SEMNon-Medicare — Revenue

$842.05M+1.5%

Questions, answered.

What is NeoGenomics's medicare and other government — NET REVENUE?

NeoGenomics (NEO) reported medicare and other government — NET REVENUE of $24.15M in Q1 2026.

How has NeoGenomics's medicare and other government — NET REVENUE changed year-over-year?

NeoGenomics's medicare and other government — NET REVENUE increased by 14.4% year-over-year, from $21.1M to $24.15M.

What is the long-term trend for NeoGenomics's medicare and other government — NET REVENUE?

Over 4 years (2021 to 2025), NeoGenomics's medicare and other government — NET REVENUE has grown at a 6.0% compound annual growth rate (CAGR), from $72.01M to $90.87M.

What does medicare and other government — NET REVENUE mean?

This metric represents the total net revenue generated from diagnostic testing services reimbursed by Medicare and other government-sponsored healthcare programs. It reflects the company's ability to capture market share within public healthcare systems and serves as a key indicator of regulatory and reimbursement stability for clinical laboratory services.